DUBLIN--(BUSINESS WIRE)--The "Drug Analysis: Feraccru" drug pipelines has been added to ResearchAndMarkets.com's offering.
Feraccru (ferric trimaltol; Shield Therapeutics/AOP Orphan Pharmaceuticals) is a novel oral ferric iron form with hematinic activity being investigated for the treatment of anemia in chronic kidney disease (CKD). The drug dissociates into ferric iron which is transported to erythroid precursor cells to be incorporated into hemoglobin. Feraccru is awaiting approval in Europe for the treatment of anemia in CKD in inflammatory bowel disease, as an alternative to intravenous iron.
Key Topics Covered:
List of Figures
Figure 1: Feraccru for anemia in chronic kidney disease - SWOT analysis
Figure 2: Drug assessment summary of Feraccru for anemia in chronic kidney disease
Figure 3: Drug assessment summary of Feraccru for anemia in chronic kidney disease
Figure 4: Feraccru sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24
List of Tables
Table 1: Feraccru drug profile
Table 2: Feraccru Phase III trials in anemia in chronic kidney disease
Table 3: Feraccru sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/wqg6zr/feraccru_ferric?w=4
